TSTickerStarGet alerts

LGVN 10-Q filed 2026-11-12 | Key takeaways

LGVN filed its 10-Q; the most relevant disclosure change is added Strategic alternatives and going concern: Company initiated strategic alternatives review process with Special Committee formed October 8, 2026 and retained Lucid Capital Markets as financial advisor October 28, 2026 to explore potential business combination; cash flow forecast indicates insufficient. Customer concentration: Customer One represented 100% of revenue; Customer One represented 100% of revenue.

Share this story

Key takeaways

  • Strategic review: Special Committee formed October 8, 2026 to oversee review of strategic alternatives; Lucid Capital Markets retained as financial advisor October 28, 2026, exploring potential business combination

  • Cash conservation: Company implemented cash conservation measures and temporary executive compensation reductions (25%-50%) effective February 2026, later restored following Private Placement

  • Reverse split: 1:10 reverse stock split effective August 26, 2026; share counts and per-share metrics adjusted retroactively across all periods presented

  • ELPIS II results: Trial did not meet primary RVEF endpoint (LS mean diff -0.7 pp, p=0.8336); MACE secondary endpoint showed statistical significance with 8 events SOC vs 1 laromestrocel (P=0.043); FDA meeting requested to determine next steps

  • Leadership changes: CMO Dr. Nataliya Agafonova stepped down October 14, 2026; Board member Ursula Ungaro resigned November 1, 2026 citing personal health issues

  • Customer concentration: 100% of contract manufacturing revenue from single customer in Q1 2026 and full-year 2025; no additional manufacturing activities planned

  • Other income: $1.0 million XPRIZE Healthspan Milestone 2 Award received in Q3 2026; $0.3 million Milestone 1 Award in Q3 2025

Key metrics

Total revenues - Q3Q3 2026
$115K-16%
Total revenues - 9MNine months 2026
$800K-4%
Net loss - Q3Q3 2026
$6.1 million15% improvement
Net loss - 9MNine months 2026
$16.9 million2% improvement
Cash and cash equivalentsSeptember 30, 2026
$7.2 million
Clinical trial revenue - Q3Q3 2026
$115K22%
Contract manufacturing revenue - Q3Q3 2026
$0-100%
Gross profit - Q3Q3 2026
$71K-43%

Customer concentration

Customer OneQ1 2026
100%Share of revenue
Customer OneFY 2025
100%Share of revenue

Disclosure changes

  • Strategic alternatives and going concern

    Company initiated strategic alternatives review process with Special Committee formed October 8, 2026 and retained Lucid Capital Markets as financial advisor October 28, 2026 to explore potential business combination; cash flow forecast indicates insufficient cash to meet minimum expenditure commitments for one year, creating substantial doubt about going concern

    Indicates potential M&A activity or fundamental strategic shift amid cash constraints and clinical trial results
  • Reverse stock split

    1:10 reverse stock split effective August 26, 2026; all share, per share, option, warrant, and equity award numbers adjusted retroactively across all periods presented

    Significant change to share structure and per-share metrics affecting shareholder dilution and stock price
  • Leadership changes - CMO and board

    CMO Dr. Nataliya Agafonova stepped down effective October 14, 2026; Board member Ursula Ungaro resigned November 1, 2026 from Board and all committees citing personal health issues (not disagreement with company)

    Key leadership transitions during critical strategic review period
  • ELPIS II trial results

    ELPS II did not meet primary RVEF endpoint (LS mean diff -0.7pp, p=0.8336) but showed statistical significance on MACE secondary endpoint (8 events SOC vs 1 laromestrocel, P=0.043); FDA meeting requested to determine next steps; trial no longer considered pivotal by FDA based on Type C meeting feedback

    Primary endpoint miss but secondary endpoint statistical significance may support continued development; FDA alignment uncertain
  • Executive compensation reduction and restoration

    Temporary 25%-50% executive compensation reduction effective February 16, 2026; restored following March 2026 Private Placement close; Board fees similarly reduced and restored

    Indicates cash conservation efforts during financing uncertainty
  • XPRIZE award

    Company selected as XPRIZE Healthspan Finalist Team receiving $1.0 million Milestone 2 Award in Q3 2026; opportunity to compete for Grand Prize up to $81 million

    Non-dilutive funding for clinical development; recognition of laromestrocel potential

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow LGVN in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert